1
|
Mechanisms for the α-Adrenoceptor-Mediated Positive Inotropy in Mouse Ventricular Myocardium: Enhancing Effect of Action Potential Prolongation. Int J Mol Sci 2023; 24:ijms24043926. [PMID: 36835338 PMCID: PMC9964142 DOI: 10.3390/ijms24043926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 02/09/2023] [Accepted: 02/13/2023] [Indexed: 02/17/2023] Open
Abstract
Mechanisms for the α-adrenoceptor-mediated positive inotropy in neonatal mouse ventricular myocardium were studied with isolated myocardial preparations. The phenylephrine-induced positive inotropy was suppressed by prazosin, nifedipine, and chelerythrine, a protein kinase C inhibitor, but not by SEA0400, a selective Na+/Ca2+ exchanger inhibitor. Phenylephrine increased the L-type Ca2+ channel current and prolonged the action potential duration, while the voltage-dependent K+ channel current was not influenced. In the presence of cromakalim, an ATP-sensitive K+ channel opener, the phenylephrine-induced prolongation of action potential duration, as well as the positive inotropy, were smaller than in the absence of cromakalim. These results suggest that the α-adrenoceptor-mediated positive inotropy is mediated by an increase in Ca2+ influx through the L-type Ca2+ channel, and the concomitant increase in action potential duration acts as an enhancing factor.
Collapse
|
2
|
Sandroni PB, Fisher-Wellman KH, Jensen BC. Adrenergic Receptor Regulation of Mitochondrial Function in Cardiomyocytes. J Cardiovasc Pharmacol 2022; 80:364-377. [PMID: 35170492 PMCID: PMC9365878 DOI: 10.1097/fjc.0000000000001241] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 02/01/2022] [Indexed: 01/31/2023]
Abstract
ABSTRACT Adrenergic receptors (ARs) are G protein-coupled receptors that are stimulated by catecholamines to induce a wide array of physiological effects across tissue types. Both α1- and β-ARs are found on cardiomyocytes and regulate cardiac contractility and hypertrophy through diverse molecular pathways. Acute activation of cardiomyocyte β-ARs increases heart rate and contractility as an adaptive stress response. However, chronic β-AR stimulation contributes to the pathobiology of heart failure. By contrast, mounting evidence suggests that α1-ARs serve protective functions that may mitigate the deleterious effects of chronic β-AR activation. Here, we will review recent studies demonstrating that α1- and β-ARs differentially regulate mitochondrial biogenesis and dynamics, mitochondrial calcium handling, and oxidative phosphorylation in cardiomyocytes. We will identify potential mechanisms of these actions and focus on the implications of these findings for the modulation of contractile function in the uninjured and failing heart. Collectively, we hope to elucidate important physiological processes through which these well-studied and clinically relevant receptors stimulate and fuel cardiac contraction to contribute to myocardial health and disease.
Collapse
Affiliation(s)
- Peyton B. Sandroni
- University of North Carolina School of Medicine, Department of Pharmacology
- University of North Carolina School of Medicine, McAllister Heart Institute
| | - Kelsey H. Fisher-Wellman
- East Carolina University Brody School of Medicine, Department of Physiology
- East Carolina University Diabetes and Obesity Institute
| | - Brian C. Jensen
- University of North Carolina School of Medicine, Department of Pharmacology
- University of North Carolina School of Medicine, McAllister Heart Institute
- University of North Carolina School of Medicine, Department of Medicine, Division of Cardiology
| |
Collapse
|
3
|
Khokhlova A, Myachina T, Volzhaninov D, Butova X, Kochurova A, Berg V, Gette I, Moroz G, Klinova S, Minigalieva I, Solovyova O, Danilova I, Sokolova K, Kopylova G, Shchepkin D. Type 1 Diabetes Impairs Cardiomyocyte Contractility in the Left and Right Ventricular Free Walls but Preserves It in the Interventricular Septum. Int J Mol Sci 2022; 23:ijms23031719. [PMID: 35163643 PMCID: PMC8836009 DOI: 10.3390/ijms23031719] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 01/28/2022] [Accepted: 01/28/2022] [Indexed: 12/14/2022] Open
Abstract
Type 1 diabetes (T1D) leads to ischemic heart disease and diabetic cardiomyopathy. We tested the hypothesis that T1D differently affects the contractile function of the left and right ventricular free walls (LV, RV) and the interventricular septum (IS) using a rat model of alloxan-induced T1D. Single-myocyte mechanics and cytosolic Ca2+ concentration transients were studied on cardiomyocytes (CM) from LV, RV, and IS in the absence and presence of mechanical load. In addition, we analyzed the phosphorylation level of sarcomeric proteins and the characteristics of the actin-myosin interaction. T1D similarly affected the characteristics of actin-myosin interaction in all studied regions, decreasing the sliding velocity of native thin filaments over myosin in an in vitro motility assay and its Ca2+ sensitivity. A decrease in the thin-filament velocity was associated with increased expression of β-myosin heavy-chain isoform. However, changes in the mechanical function of single ventricular CM induced by T1D were different. T1D depressed the contractility of CM from LV and RV; it decreased the auxotonic tension amplitude and the slope of the active tension–length relationship. Nevertheless, the contractile function of CM from IS was principally preserved.
Collapse
Affiliation(s)
- Anastasia Khokhlova
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
- Institute of Physics and Technology, Ural Federal University, Mira 19, 620002 Yekaterinburg, Russia
- Correspondence:
| | - Tatiana Myachina
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Denis Volzhaninov
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Xenia Butova
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Anastasia Kochurova
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Valentina Berg
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Irina Gette
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Gleb Moroz
- Institute of Natural Sciences and Mathematics, Ural Federal University, Mira 19, 620002 Yekaterinburg, Russia;
| | - Svetlana Klinova
- Yekaterinburg Medical Research Center for Prophylaxis and Health Protection in Industrial Workers, Popova 30, 620014 Yekaterinburg, Russia; (S.K.); (I.M.)
| | - Ilzira Minigalieva
- Yekaterinburg Medical Research Center for Prophylaxis and Health Protection in Industrial Workers, Popova 30, 620014 Yekaterinburg, Russia; (S.K.); (I.M.)
| | - Olga Solovyova
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
- Institute of Physics and Technology, Ural Federal University, Mira 19, 620002 Yekaterinburg, Russia
- Institute of Natural Sciences and Mathematics, Ural Federal University, Mira 19, 620002 Yekaterinburg, Russia;
| | - Irina Danilova
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Ksenia Sokolova
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Galina Kopylova
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| | - Daniil Shchepkin
- Institute of Immunology and Physiology, Russian Academy of Sciences, Pervomajskaya 106, 620049 Yekaterinburg, Russia; (T.M.); (D.V.); (X.B.); (A.K.); (V.B.); (I.G.); (O.S.); (I.D.); (K.S.); (G.K.); (D.S.)
| |
Collapse
|
4
|
Kovács Á, Herwig M, Budde H, Delalat S, Kolijn D, Bódi B, Hassoun R, Tangos M, Zhazykbayeva S, Balogh Á, Czuriga D, Van Linthout S, Tschöpe C, Dhalla NS, Mügge A, Tóth A, Papp Z, Barta J, Hamdani N. Interventricular Differences of Signaling Pathways-Mediated Regulation of Cardiomyocyte Function in Response to High Oxidative Stress in the Post-Ischemic Failing Rat Heart. Antioxidants (Basel) 2021; 10:antiox10060964. [PMID: 34208541 PMCID: PMC8234177 DOI: 10.3390/antiox10060964] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 05/20/2021] [Accepted: 06/08/2021] [Indexed: 01/09/2023] Open
Abstract
Standard heart failure (HF) therapies have failed to improve cardiac function or survival in HF patients with right ventricular (RV) dysfunction suggesting a divergence in the molecular mechanisms of RV vs. left ventricular (LV) failure. Here we aimed to investigate interventricular differences in sarcomeric regulation and function in experimental myocardial infarction (MI)-induced HF with reduced LV ejection fraction (HFrEF). MI was induced by LAD ligation in Sprague-Dawley male rats. Sham-operated animals served as controls. Eight weeks after intervention, post-ischemic HFrEF and Sham animals were euthanized. Heart tissue samples were deep-frozen stored (n = 3-5 heart/group) for ELISA, kinase activity assays, passive stiffness and Ca2+-sensitivity measurements on isolated cardiomyocytes, phospho-specific Western blot, and PAGE of contractile proteins, as well as for collagen gene expressions. Markers of oxidative stress and inflammation showed interventricular differences in post-ischemic rats: TGF-β1, lipid peroxidation, and 3-nitrotyrosine levels were higher in the LV than RV, while hydrogen peroxide, VCAM-1, TNFα, and TGF-β1 were increased in both ventricles. In addition, nitric oxide (NO) level was significantly decreased, while FN-1 level was significantly increased only in the LV, but both were unchanged in RV. CaMKII activity showed an 81.6% increase in the LV, in contrast to a 38.6% decrease in the RV of HFrEF rats. Cardiomyocyte passive stiffness was higher in the HFrEF compared to the Sham group as evident from significantly steeper Fpassive vs. sarcomere length relationships. In vitro treatment with CaMKIIδ, however, restored cardiomyocyte passive stiffness only in the HFrEF RV, but had no effect in the HFrEF LV. PKG activity was lower in both ventricles in the HFrEF compared to the Sham group. In vitro PKG administration decreased HFrEF cardiomyocyte passive stiffness; however, the effect was more pronounced in the HFrEF LV than HFrEF RV. In line with this, we observed distinct changes of titin site-specific phosphorylation in the RV vs. LV of post-ischemic rats, which may explain divergent cardiomyocyte stiffness modulation observed. Finally, Ca2+-sensitivity of RV cardiomyocytes was unchanged, while LV cardiomyocytes showed increased Ca2+-sensitivity in the HFrEF group. This could be explained by decreased Ser-282 phosphorylation of cMyBP-C by 44.5% in the RV, but without any alteration in the LV, while Ser-23/24 phosphorylation of cTnI was decreased in both ventricles in the HFrEF vs. the Sham group. Our data pointed to distinct signaling pathways-mediated phosphorylations of sarcomeric proteins for the RV and LV of the post-ischemic failing rat heart. These results implicate divergent responses for oxidative stress and open a new avenue in targeting the RV independently of the LV.
Collapse
Affiliation(s)
- Árpád Kovács
- Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (Á.K.); (B.B.); (A.T.); (Z.P.)
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Melissa Herwig
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Heidi Budde
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Simin Delalat
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Detmar Kolijn
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Beáta Bódi
- Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (Á.K.); (B.B.); (A.T.); (Z.P.)
| | - Roua Hassoun
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Melina Tangos
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Saltanat Zhazykbayeva
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Ágnes Balogh
- Department of Cardiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (Á.B.); (D.C.); (J.B.)
| | - Dániel Czuriga
- Department of Cardiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (Á.B.); (D.C.); (J.B.)
| | - Sophie Van Linthout
- Berlin Institute of Health at Charite (BIH)-Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany; (S.V.L.); (C.T.)
| | - Carsten Tschöpe
- Berlin Institute of Health at Charite (BIH)-Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany; (S.V.L.); (C.T.)
| | - Naranjan S. Dhalla
- Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, 351 Tache Avenue, Department of Physiology and Pathophysiology, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R2H 2A6, Canada;
| | - Andreas Mügge
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
| | - Attila Tóth
- Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (Á.K.); (B.B.); (A.T.); (Z.P.)
- HAS-UD Vascular Biology and Myocardial Pathophysiology Research Group, Hungarian Academy of Sciences, H-4032 Debrecen, Hungary
| | - Zoltán Papp
- Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (Á.K.); (B.B.); (A.T.); (Z.P.)
- HAS-UD Vascular Biology and Myocardial Pathophysiology Research Group, Hungarian Academy of Sciences, H-4032 Debrecen, Hungary
| | - Judit Barta
- Department of Cardiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (Á.B.); (D.C.); (J.B.)
| | - Nazha Hamdani
- Institut für Forschung und Lehre (IFL) Molecular and Experimental Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany; (M.H.); (H.B.); (S.D.); (D.K.); (R.H.); (M.T.); (S.Z.); (A.M.)
- Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, 44801 Bochum, Germany
- Correspondence: ; Tel.: +49-234-5095-9053
| |
Collapse
|
5
|
Walsh SK, Lipina C, Ang SY, Sato M, Chia LY, Kocan M, Hutchinson DS, Summers RJ, Wainwright CL. GPR55 regulates the responsiveness to, but does not dimerise with, α 1A-adrenoceptors. Biochem Pharmacol 2021; 188:114560. [PMID: 33844984 DOI: 10.1016/j.bcp.2021.114560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 03/26/2021] [Accepted: 04/06/2021] [Indexed: 11/15/2022]
Abstract
Emerging evidence suggests that G protein coupled receptor 55 (GPR55) may influence adrenoceptor function/activity in the cardiovascular system. Whether this reflects direct interaction (dimerization) between receptors or signalling crosstalk has not been investigated. This study explored the interaction between GPR55 and the alpha 1A-adrenoceptor (α1A-AR) in the cardiovascular system and the potential to influence function/signalling activities. GPR55 and α1A-AR mediated changes in both cardiac and vascular function was assessed in male wild-type (WT) and GPR55 homozygous knockout (GPR55-/-) mice by pressure volume loop analysis and isolated vessel myography, respectively. Dimerization of GPR55 with the α1A-AR was examined in transfected Chinese hamster ovary-K1 (CHO-K1) cells via Bioluminescence Resonance Energy Transfer (BRET). GPR55 and α1A-AR mediated signalling (extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation) was investigated in neonatal rat ventricular cardiomyocytes using AlphaScreen proximity assays. GPR55-/- mice exhibited both enhanced pressor and inotropic responses to A61603 (α1A-AR agonist), while in isolated vessels, A61603 induced vasoconstriction was attenuated by a GPR55-dependent mechanism. Conversely, GPR55-mediated vasorelaxation was not altered by pharmacological blockade of α1A-ARs with tamsulosin. While cellular studies demonstrated that GPR55 and α1A-AR failed to dimerize, pharmacological blockade of GPR55 altered α1A-AR mediated signalling and reduced ERK1/2 phosphorylation. Taken together, this study provides evidence that GPR55 and α1A-AR do not dimerize to form heteromers, but do interact at the signalling level to modulate the function of α1A-AR in the cardiovascular system.
Collapse
Affiliation(s)
- Sarah K Walsh
- Cardiometabolic Health Research, School of Pharmacy and Life Sciences, Robert Gordon University, Sir Ian Wood Building, Aberdeen AB10 7GJ, UK.
| | - Christopher Lipina
- Division of Cell Signalling and Immunology, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK
| | - Sheng Y Ang
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Masaaki Sato
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Ling Yeong Chia
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Martina Kocan
- The Florey Institute of Neuroscience and Mental Health and School of Biosciences, University of Melbourne, Parkville, VIC, Australia
| | - Dana S Hutchinson
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Roger J Summers
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Cherry L Wainwright
- Cardiometabolic Health Research, School of Pharmacy and Life Sciences, Robert Gordon University, Sir Ian Wood Building, Aberdeen AB10 7GJ, UK
| |
Collapse
|
6
|
Joyce W, Scholman KT, Jensen B, Wang T, Boukens BJ. α 1-adrenergic stimulation increases ventricular action potential duration in the intact mouse heart. Facets (Ott) 2021. [DOI: 10.1139/facets-2020-0081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The role of α1-adrenergic receptors (α-ARs) in the regulation of myocardial function is less well-understood than that of β-ARs. Previous reports in the mouse heart have described that α1-adrenergic stimulation shortens action potential duration in isolated cells or tissues, in contrast to prolongation of the action potential reported in most other mammalian hearts. It has since become appreciated, however, that the mouse heart exhibits marked variation in inotropic response to α1-adrenergic stimulation between ventricles and even individual cardiomyocytes. We investigated the effects of α1-adrenergic stimulation on action potential duration at 80% of repolarization in the right and left ventricles of Langendorff-perfused mouse hearts using optical mapping. In hearts under β-adrenergic blockade (propranolol), phenylephrine or noradrenaline perfusion both increased action potential duration in both ventricles. The increased action potential duration was partially reversed by subsequent perfusion with the α-adrenergic antagonist phentolamine (1 μmol L−1). These data show that α1-receptor stimulation may lead to a prolonging of action potential in the mouse heart and thereby refine our understanding of how action potential duration adjusts during sympathetic stimulation.
Collapse
Affiliation(s)
- William Joyce
- Department of Biology—Zoophysiology, Aarhus University, DK-8000 Aarhus C, Denmark
- Department of Biology, University of Ottawa, 30 Marie Curie, Ottawa, ON K1N 6N5, Canada
| | - Koen T. Scholman
- Department of Medical Biology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 11005 AZ Amsterdam, the Netherlands
| | - Bjarke Jensen
- Department of Medical Biology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 11005 AZ Amsterdam, the Netherlands
| | - Tobias Wang
- Department of Biology—Zoophysiology, Aarhus University, DK-8000 Aarhus C, Denmark
| | - Bastiaan J. Boukens
- Department of Medical Biology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 11005 AZ Amsterdam, the Netherlands
- Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1100 DD Amsterdam, the Netherlands
| |
Collapse
|
7
|
Zhang J, Simpson PC, Jensen BC. Cardiac α1A-adrenergic receptors: emerging protective roles in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2020; 320:H725-H733. [PMID: 33275531 DOI: 10.1152/ajpheart.00621.2020] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
α1-Adrenergic receptors (ARs) are catecholamine-activated G protein-coupled receptors (GPCRs) that are expressed in mouse and human myocardium and vasculature, and play essential roles in the regulation of cardiovascular physiology. Though α1-ARs are less abundant in the heart than β1-ARs, activation of cardiac α1-ARs results in important biologic processes such as hypertrophy, positive inotropy, ischemic preconditioning, and protection from cell death. Data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) indicate that nonselectively blocking α1-ARs is associated with a twofold increase in adverse cardiac events, including heart failure and angina, suggesting that α1-AR activation might also be cardioprotective in humans. Mounting evidence implicates the α1A-AR subtype in these adaptive effects, including prevention and reversal of heart failure in animal models by α1A agonists. In this review, we summarize recent advances in our understanding of cardiac α1A-ARs.
Collapse
Affiliation(s)
- Jiandong Zhang
- McAllister Heart Institute, University of North Carolina, School of Medicine, Chapel Hill, North Carolina
| | - Paul C Simpson
- Department of Medicine and Research Service, San Francisco Veterans Affairs Medical Center and Cardiovascular Research Institute, University of California, San Francisco, California
| | - Brian C Jensen
- McAllister Heart Institute, University of North Carolina, School of Medicine, Chapel Hill, North Carolina
| |
Collapse
|
8
|
Nollet EE, Manders EM, Goebel M, Jansen V, Brockmann C, Osinga J, van der Velden J, Helmes M, Kuster DWD. Large-Scale Contractility Measurements Reveal Large Atrioventricular and Subtle Interventricular Differences in Cultured Unloaded Rat Cardiomyocytes. Front Physiol 2020; 11:815. [PMID: 32848817 PMCID: PMC7396550 DOI: 10.3389/fphys.2020.00815] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 06/18/2020] [Indexed: 01/22/2023] Open
Abstract
The chambers of the heart fulfill different hemodynamic functions, which are reflected in their structural and contractile properties. While the atria are highly elastic to allow filling from the venous system, the ventricles need to be able to produce sufficiently high pressures to eject blood into the circulation. The right ventricle (RV) pumps into the low pressure pulmonary circulation, while the left ventricle (LV) needs to overcome the high pressure of the systemic circulation. It is incompletely understood whether these differences can be explained by the contractile differences at the level of the individual cardiomyocytes of the chambers. We addressed this by isolating cardiomyocytes from atria, RV, LV, and interventricular septum (IVS) of five healthy wild-type rats. Using a high-throughput contractility set-up, we measured contractile function of 2,043 cells after overnight culture. Compared to ventricular cardiomyocytes, atrial cells showed a twofold lower contraction amplitude and 1.4- to 1.7-fold slower kinetics of contraction and relaxation. The interventricular differences in contractile function were much smaller; RV cells displayed 12–13% less fractional shortening and 5–9% slower contraction and 3–15% slower relaxation kinetics relative to their LV and IVS counterparts. Aided by a large dataset, we established relationships between contractile parameters and found contraction velocity, fractional shortening and relaxation velocity to be highly correlated. In conclusion, our findings are in line with contractile differences observed at the atrioventricular level, but can only partly explain the interventricular differences that exist at the organ level.
Collapse
Affiliation(s)
- Edgar E Nollet
- Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | | | - Max Goebel
- Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Valentijn Jansen
- Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Cord Brockmann
- Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Jorrit Osinga
- Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Jolanda van der Velden
- Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Michiel Helmes
- Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands.,CytoCypher BV, Wageningen, Netherlands
| | - Diederik W D Kuster
- Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| |
Collapse
|
9
|
Wang TY, Arking DE, Maleszewski JJ, Fox-Talbot K, Nieuwenhuis TO, Santhanam L, Virmani R, Rosenberg AZ, Halushka MK. Human cardiac myosin light chain 4 (MYL4) mosaic expression patterns vary by sex. Sci Rep 2019; 9:12681. [PMID: 31481666 PMCID: PMC6722118 DOI: 10.1038/s41598-019-49191-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Accepted: 08/21/2019] [Indexed: 11/17/2022] Open
Abstract
Sex disparities modulate cardiac function, although the proteins and mechanisms remain to be elucidated. We recently demonstrated a mosaic pattern of protein expression in the heart for over 100 proteins. Here we investigate one of these proteins, myosin light chain 4 (MYL4), which is important for contractile functions by increasing force production. We assayed the expression pattern of MYL4 across 756 ventricular myocardial samples from 668 individuals utilizing a semi-automated Cell Profiler method on five tissue microarrays (TMAs) of cardiac tissues across a diverse set of diseases. The percentage of MYL4 positive cells was significantly higher in male subjects independently across all five TMAs, regardless of disease state (p = 8.66e-15). Higher MYL4 expression was also modestly associated with hypertrophic cardiomyopathy (p = 6.3e-04). MYL4 expression did not associate with sudden cardiac death or other cardiomyopathies. This study demonstrates a new mosaic pattern of protein expression that underlies sex disparities in the human heart.
Collapse
Affiliation(s)
- Tony Y Wang
- Division of Cardiovascular Pathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Dan E Arking
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Joseph J Maleszewski
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
| | - Karen Fox-Talbot
- Division of Cardiovascular Pathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Tim O Nieuwenhuis
- Division of Cardiovascular Pathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Lakshmi Santhanam
- Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | - Avi Z Rosenberg
- Division of Renal Pathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Marc K Halushka
- Division of Cardiovascular Pathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
| |
Collapse
|
10
|
Cardiomyocytes have mosaic patterns of protein expression. Cardiovasc Pathol 2018; 34:50-57. [PMID: 29677652 PMCID: PMC5940500 DOI: 10.1016/j.carpath.2018.03.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Revised: 03/04/2018] [Accepted: 03/19/2018] [Indexed: 12/29/2022] Open
Abstract
Skeletal myocytes have well-established fast and slow twitch fibers with unique gene and protein specific expression patterns. By immunohistochemical staining, these show a mosaic pattern across myocytes. We hypothesized cardiac myocytes may behave similarly where some proteins are differentially expressed between mature cardiomyocytes. We utilized the tool HPASubC on over 52,000 cardiac images of the Human Protein Atlas to identify differential protein expression patterns by immunohistochemistry across the cardiomyocytes. We matched identified proteins to open chromatin and gene expression data. We identified 143 putative proteins with mosaic patterns of expression across the cardiomyocytes. We validated four of these proteins (MYL3, MYL4, PAM, and MYOM1) and demonstrated unique atrial or ventricular patterns of expression for each. Acetylation of histone H3K27 at the promoters of these four genes were consistent with the atrial/ventricular expression patterns. Despite the generally accepted homogeneity of cardiomyocytes, a small subset of proteins varies between cardiomyocytes in a mosaic pattern. This fundamental process has been previously uncharacterized. These changes may inform on different functional and disease-related activities of proteins in individual cardiomyocytes.
Collapse
|
11
|
Myagmar BE, Flynn JM, Cowley PM, Swigart PM, Montgomery MD, Thai K, Nair D, Gupta R, Deng DX, Hosoda C, Melov S, Baker AJ, Simpson PC. Adrenergic Receptors in Individual Ventricular Myocytes: The Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent. Circ Res 2017; 120:1103-1115. [PMID: 28219977 DOI: 10.1161/circresaha.117.310520] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2017] [Revised: 02/13/2017] [Accepted: 02/17/2017] [Indexed: 12/20/2022]
Abstract
RATIONALE It is unknown whether every ventricular myocyte expresses all 5 of the cardiac adrenergic receptors (ARs), β1, β2, β3, α1A, and α1B. The β1 and β2 are thought to be the dominant myocyte ARs. OBJECTIVE Quantify the 5 cardiac ARs in individual ventricular myocytes. METHODS AND RESULTS We studied ventricular myocytes from wild-type mice, mice with α1A and α1B knockin reporters, and β1 and β2 knockout mice. Using individual isolated cells, we measured knockin reporters, mRNAs, signaling (phosphorylation of extracellular signal-regulated kinase and phospholamban), and contraction. We found that the β1 and α1B were present in all myocytes. The α1A was present in 60%, with high levels in 20%. The β2 and β3 were detected in only ≈5% of myocytes, mostly in different cells. In intact heart, 30% of total β-ARs were β2 and 20% were β3, both mainly in nonmyocytes. CONCLUSION The dominant ventricular myocyte ARs present in all cells are the β1 and α1B. The β2 and β3 are mostly absent in myocytes but are abundant in nonmyocytes. The α1A is in just over half of cells, but only 20% have high levels. Four distinct myocyte AR phenotypes are defined: 30% of cells with β1 and α1B only; 60% that also have the α1A; and 5% each that also have the β2 or β3. The results raise cautions in experimental design, such as receptor overexpression in myocytes that do not express the AR normally. The data suggest new paradigms in cardiac adrenergic signaling mechanisms.
Collapse
Affiliation(s)
- Bat-Erdene Myagmar
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - James M Flynn
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Patrick M Cowley
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Philip M Swigart
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Megan D Montgomery
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Kevin Thai
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Divya Nair
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Rumita Gupta
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - David X Deng
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Chihiro Hosoda
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Simon Melov
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Anthony J Baker
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.)
| | - Paul C Simpson
- From the Department of Medicine, VA Medical Center, San Francisco, CA (B.-E.M., P.M.C., P.M.S., M.D.M., K.T., D.N., R.G., D.X.D., C.H., A.J.B., P.C.S.); Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco (B.-E.M., P.M.C., M.D.M., D.X.D., C.H., A.J.B., P.C.S.); and Buck Institute for Research on Aging, Novato, CA (J.M.F., S.M.).
| |
Collapse
|
12
|
Wood BM, Bossuyt J. Emergency Spatiotemporal Shift: The Response of Protein Kinase D to Stress Signals in the Cardiovascular System. Front Pharmacol 2017; 8:9. [PMID: 28174535 PMCID: PMC5258689 DOI: 10.3389/fphar.2017.00009] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Accepted: 01/04/2017] [Indexed: 12/12/2022] Open
Abstract
Protein Kinase D isoforms (PKD 1-3) are key mediators of neurohormonal, oxidative, and metabolic stress signals. PKDs impact a wide variety of signaling pathways and cellular functions including actin dynamics, vesicle trafficking, cell motility, survival, contractility, energy substrate utilization, and gene transcription. PKD activity is also increasingly linked to cancer, immune regulation, pain modulation, memory, angiogenesis, and cardiovascular disease. This increasing complexity and diversity of PKD function, highlights the importance of tight spatiotemporal control of the kinase via protein–protein interactions, post-translational modifications or targeting via scaffolding proteins. In this review, we focus on the spatiotemporal regulation and effects of PKD signaling in response to neurohormonal, oxidant and metabolic signals that have implications for myocardial disease. Precise targeting of these mechanisms will be crucial in the design of PKD-based therapeutic strategies.
Collapse
Affiliation(s)
- Brent M Wood
- Department of Pharmacology, University of California, Davis, Davis CA, USA
| | - Julie Bossuyt
- Department of Pharmacology, University of California, Davis, Davis CA, USA
| |
Collapse
|
13
|
Molina CE, Heijman J, Dobrev D. Differences in Left Versus Right Ventricular Electrophysiological Properties in Cardiac Dysfunction and Arrhythmogenesis. Arrhythm Electrophysiol Rev 2016; 5:14-9. [PMID: 27403288 DOI: 10.15420/aer.2016.8.2] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
A wide range of ion channels, transporters, signaling pathways and tissue structure at a microscopic and macroscopic scale regulate the electrophysiological activity of the heart. Each region of the heart has optimised these properties based on its specific role during the cardiac cycle, leading to well-established differences in electrophysiology, Ca(2+) handling and tissue structure between atria and ventricles and between different layers of the ventricular wall. Similarly, the right ventricle (RV) and left ventricle (LV) have different embryological, structural, metabolic and electrophysiological features, but whether interventricular differences promote differential remodeling leading to arrhythmias is not well understood. In this article, we will summarise the available data on intrinsic differences between LV and RV electrophysiology and indicate how these differences affect cardiac function. Furthermore, we will discuss the differential remodeling of both chambers in pathological conditions and its potential impact on arrhythmogenesis.
Collapse
Affiliation(s)
- Cristina E Molina
- Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Essen, Germany
| | - Jordi Heijman
- Cardiovascular Research Institute Maastricht, Faculty of Health, Medicine, and Life Sciences, Maastricht University, Maastricht, The Netherlands
| | - Dobromir Dobrev
- Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Essen, Germany
| |
Collapse
|
14
|
Han AJ, Slomka T, Mehrotra A, Murillo LC, Alsafwah SF, Khouzam RN. Paradoxical Hemodynamic Instability After Pericardial Window. Echocardiography 2016; 33:1251-2. [PMID: 27046800 DOI: 10.1111/echo.13229] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Paradoxical hemodynamic instability (PHI), also called postoperative low cardiac output syndrome (LCOS), is a rare but fatal complication after drainage of a pericardial effusion (PEf). This condition usually develops within hours postprocedure and appears unrelated to the method of drainage. The exact mechanism of this condition is not well understood. We present a case of an 84-year-old patient with no previous cardiac or cancer history who presented with acute shortness of breath (SOB). Computed tomography (CT) ruled out pulmonary embolism and echocardiography confirmed early tamponade. Following emergent subxiphoid pericardiectomy, the patient developed hemodynamic instability and shock and subsequent multiorgan failure. Repeat echocardiography revealed left ventricular (LV) hypercontractility and new right ventricular (RV) dilatation with akinesis. The patient's condition continued to deteriorate in spite of maximal doses of pressors. The patient died after the family's request to discontinue further extraordinary measures.
Collapse
Affiliation(s)
- Andrew J Han
- Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Teresa Slomka
- Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Anurag Mehrotra
- Division of Pulmonary Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Luis C Murillo
- Division of Pulmonary Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Shadwan F Alsafwah
- Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Rami N Khouzam
- Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
| |
Collapse
|
15
|
Cowley PM, Wang G, Chang AN, Makwana O, Swigart PM, Lovett DH, Stull JT, Simpson PC, Baker AJ. The α1A-adrenergic receptor subtype mediates increased contraction of failing right ventricular myocardium. Am J Physiol Heart Circ Physiol 2015; 309:H888-96. [PMID: 26116709 DOI: 10.1152/ajpheart.00042.2015] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 06/24/2015] [Indexed: 12/23/2022]
Abstract
Dysfunction of the right ventricle (RV) is closely related to prognosis for patients with RV failure. Therefore, strategies to improve failing RV function are significant. In a mouse RV failure model, we previously reported that α1-adrenergic receptor (α1-AR) inotropic responses are increased. The present study determined the roles of both predominant cardiac α1-AR subtypes (α1A and α1B) in upregulated inotropy in failing RV. We used the mouse model of bleomycin-induced pulmonary fibrosis, pulmonary hypertension, and RV failure. We assessed the myocardial contractile response in vitro to stimulation of the α1A-subtype (using α1A-subtype-selective agonist A61603) and α1B-subtype [using α1A-subtype knockout mice and nonsubtype selective α1-AR agonist phenylephrine (PE)]. In wild-type nonfailing RV, a negative inotropic effect of α1-AR stimulation with PE (force decreased ≈50%) was switched to a positive inotropic effect (PIE) with bleomycin-induced RV injury. Upregulated inotropy in failing RV occurred with α1A-subtype stimulation (force increased ≈200%), but not with α1B-subtype stimulation (force decreased ≈50%). Upregulated inotropy mediated by the α1A-subtype involved increased activator Ca(2+) transients and increased phosphorylation of myosin regulatory light chain (a mediator of increased myofilament Ca(2+) sensitivity). In failing RV, the PIE elicited by the α1A-subtype was appreciably less when the α1A-subtype was stimulated in combination with the α1B-subtype, suggesting functional antagonism between α1A- and α1B-subtypes. In conclusion, upregulation of α1-AR inotropy in failing RV myocardium requires the α1A-subtype and is opposed by the α1B-subtype. The α1A subtype might be a therapeutic target to improve the function of the failing RV.
Collapse
Affiliation(s)
- Patrick M Cowley
- Veterans Affairs Medical Center, San Francisco, and Department of Medicine, University California San Francisco, San Francisco, California; and
| | - Guanying Wang
- Veterans Affairs Medical Center, San Francisco, and Department of Medicine, University California San Francisco, San Francisco, California; and
| | - Audrey N Chang
- Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Om Makwana
- Veterans Affairs Medical Center, San Francisco, and Department of Medicine, University California San Francisco, San Francisco, California; and
| | - Philip M Swigart
- Veterans Affairs Medical Center, San Francisco, and Department of Medicine, University California San Francisco, San Francisco, California; and
| | - David H Lovett
- Veterans Affairs Medical Center, San Francisco, and Department of Medicine, University California San Francisco, San Francisco, California; and
| | - James T Stull
- Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Paul C Simpson
- Veterans Affairs Medical Center, San Francisco, and Department of Medicine, University California San Francisco, San Francisco, California; and
| | - Anthony J Baker
- Veterans Affairs Medical Center, San Francisco, and Department of Medicine, University California San Francisco, San Francisco, California; and
| |
Collapse
|
16
|
Tsirkin VI, Nozdrachev AD, Korotaeva YV. The effect of histidine on the contractility and adrenoreactivity of the myocardium of nonpregnant and pregnant rats. DOKLADY BIOLOGICAL SCIENCES : PROCEEDINGS OF THE ACADEMY OF SCIENCES OF THE USSR, BIOLOGICAL SCIENCES SECTIONS 2015; 460:12-6. [PMID: 25773242 DOI: 10.1134/s0012496615010123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Indexed: 11/22/2022]
Affiliation(s)
- V I Tsirkin
- Kazan State Medical University, ul. Derendyaeva 50, Kirov, 610017, Russia,
| | | | | |
Collapse
|
17
|
Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation. J Cardiovasc Pharmacol 2014; 63:291-301. [PMID: 24145181 DOI: 10.1097/fjc.0000000000000032] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Alpha-1-adrenergic receptors (ARs) are G protein-coupled receptors activated by catecholamines. The alpha-1A and alpha-1B subtypes are expressed in mouse and human myocardium, whereas the alpha-1D protein is found only in coronary arteries. There are far fewer alpha-1-ARs than beta-ARs in the nonfailing heart, but their abundance is maintained or increased in the setting of heart failure, which is characterized by pronounced chronic elevation of catecholamines and beta-AR dysfunction. Decades of evidence from gain and loss-of-function studies in isolated cardiac myocytes and numerous animal models demonstrate important adaptive functions for cardiac alpha-1-ARs to include physiological hypertrophy, positive inotropy, ischemic preconditioning, and protection from cell death. Clinical trial data indicate that blocking alpha-1-ARs is associated with incident heart failure in patients with hypertension. Collectively, these findings suggest that alpha-1-AR activation might mitigate the well-recognized toxic effects of beta-ARs in the hyperadrenergic setting of chronic heart failure. Thus, exogenous cardioselective activation of alpha-1-ARs might represent a novel and viable approach to the treatment of heart failure.
Collapse
|
18
|
Lovett DH, Chu C, Wang G, Ratcliffe MB, Baker AJ. A N-terminal truncated intracellular isoform of matrix metalloproteinase-2 impairs contractility of mouse myocardium. Front Physiol 2014; 5:363. [PMID: 25309453 PMCID: PMC4174733 DOI: 10.3389/fphys.2014.00363] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 09/03/2014] [Indexed: 02/05/2023] Open
Abstract
The full-length isoform of matrixmetalloproteinase-2 (FL-MMP-2) plays a role in turnover of the cardiac extracellular matrix. FL-MMP-2 is also present intracellularly in association with sarcomeres and, in the setting of oxidative stress, cleaves myofilament proteins with resultant impaired contractility. Recently, a novel N-terminal truncated MMP-2 isoform (NTT-MMP-2) generated during oxidative stress was identified and shown to induce severe systolic failure; however, the injury mechanisms remained unclear. In this study, cardiac-specific NTT-MMP-2 transgenic mice were used to determine the physiological effects of NTT-MMP-2 on: force development of intact myocardium; the function of cardiac myofilaments in demembranated myocardium; and on intracellular Ca2+ transients in isolated myocytes. We related the contractile defects arising from NTT-MMP-2 expression to the known intracellular locations of NTT-MMP-2 determined using immunohistochemistry. Comparison was made with the pathophysiology arising from cardiac-specific FL-MMP-2 transgenic mice. Consistent with previous studies, FL-MMP-2 was localized to myofilaments, while NTT-MMP-2 was concentrated within subsarcolemmal mitochondria and to sites in register with the Z-line. NTT-MMP-2 expression caused a 50% reduction of force development by intact myocardium. However, NTT-MMP-2 expression did not reduce myofilament force development, consistent with the lack of NTT-MMP-2 localization to myofilaments. NTT-MMP-2 expression caused a 50% reduction in the amplitude of Ca2+ transients, indicating impaired activation. Conclusions: Unlike FL-MMP-2, NTT-MMP-2 does not mediate myofilament damage. Instead, NTT-MMP-2 causes impaired myocyte activation, which may involve effects due to localization in mitochondria and/or to transverse tubules affecting Ca2+ transients. Thus, FL-MMP-2 and NTT-MMP-2 have discrete intracellular locations and mediate different intracellular damage to cardiac myocytes.
Collapse
Affiliation(s)
- David H Lovett
- Cardiology Division, San Francisco Veteran Affairs Medical Center San Francisco, CA, USA ; Department of Medicine, University of California, San Francisco San Francisco, CA, USA
| | - Charles Chu
- Cardiology Division, San Francisco Veteran Affairs Medical Center San Francisco, CA, USA ; Department of Medicine, University of California, San Francisco San Francisco, CA, USA
| | - Guanying Wang
- Cardiology Division, San Francisco Veteran Affairs Medical Center San Francisco, CA, USA ; Department of Medicine, University of California, San Francisco San Francisco, CA, USA
| | - Mark B Ratcliffe
- Cardiology Division, San Francisco Veteran Affairs Medical Center San Francisco, CA, USA ; Department of Surgery, University of California, San Francisco San Francisco, CA, USA ; Joint UC Berkeley/UCSF Bioengineering Group San Francisco, CA, USA
| | - Anthony J Baker
- Cardiology Division, San Francisco Veteran Affairs Medical Center San Francisco, CA, USA ; Department of Medicine, University of California, San Francisco San Francisco, CA, USA
| |
Collapse
|
19
|
Tsirkin VI, Nozdrachev AD, Korotaeva YV. An endogenous sensitizer of β adrenergic receptors and its analogs attenuate the inhibition of β adrenergic receptors by propranolol and atenolol in the rat myocardium. DOKLADY BIOLOGICAL SCIENCES : PROCEEDINGS OF THE ACADEMY OF SCIENCES OF THE USSR, BIOLOGICAL SCIENCES SECTIONS 2014; 456:169-72. [PMID: 24985507 DOI: 10.1134/s001249661403017x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/25/2013] [Indexed: 11/23/2022]
Affiliation(s)
- V I Tsirkin
- Kazan State Medical University, Kazan, Republic of Tatarstan, Russia,
| | | | | |
Collapse
|
20
|
O'Connell TD, Jensen BC, Baker AJ, Simpson PC. Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev 2013; 66:308-33. [PMID: 24368739 DOI: 10.1124/pr.112.007203] [Citation(s) in RCA: 132] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Adrenergic receptors (AR) are G-protein-coupled receptors (GPCRs) that have a crucial role in cardiac physiology in health and disease. Alpha1-ARs signal through Gαq, and signaling through Gq, for example, by endothelin and angiotensin receptors, is thought to be detrimental to the heart. In contrast, cardiac alpha1-ARs mediate important protective and adaptive functions in the heart, although alpha1-ARs are only a minor fraction of total cardiac ARs. Cardiac alpha1-ARs activate pleiotropic downstream signaling to prevent pathologic remodeling in heart failure. Mechanisms defined in animal and cell models include activation of adaptive hypertrophy, prevention of cardiac myocyte death, augmentation of contractility, and induction of ischemic preconditioning. Surprisingly, at the molecular level, alpha1-ARs localize to and signal at the nucleus in cardiac myocytes, and, unlike most GPCRs, activate "inside-out" signaling to cause cardioprotection. Contrary to past opinion, human cardiac alpha1-AR expression is similar to that in the mouse, where alpha1-AR effects are seen most convincingly in knockout models. Human clinical studies show that alpha1-blockade worsens heart failure in hypertension and does not improve outcomes in heart failure, implying a cardioprotective role for human alpha1-ARs. In summary, these findings identify novel functional and mechanistic aspects of cardiac alpha1-AR function and suggest that activation of cardiac alpha1-AR might be a viable therapeutic strategy in heart failure.
Collapse
Affiliation(s)
- Timothy D O'Connell
- VA Medical Center (111-C-8), 4150 Clement St., San Francisco, CA 94121. ; or Dr. Timothy D. O'Connell, E-mail:
| | | | | | | |
Collapse
|